11:08 AM
 | 
Jan 26, 2018
 |  BC Extra  |  Company News

FDA approves Novartis' Lutathera for GEP-NETs

FDA approved Lutathera (177-Lu-Dotatate) from Novartis AG (NYSE:NVS; SIX:NOVN) to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults, including foregut, midgut, and hindgut neuroendocrine tumors. Novartis gained the drug when it acquired Advanced...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >